Bristol Myers Squibb buys Karuna Therapeutics for $14 billion, reveals the Wall Street Journal

The US biotechnology dealmaking wave rumbles on.

This time round pharmaceutical giant Bristol Myers Squibb is paying $14 billion for Karuna Therapeutics, which is developing a drug for shizophrenia.

According to the Wall Street Journal, Bristol Myers Squibb is offering $330 a share in cash for Karuna. Below is a link to the WSJ scoop:..